On Monday evening, the Food and Drug Administration approved Novo Nordisk’s high-dose oral formulation of semaglutide for ...
Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 23, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...
Key market opportunities for liraglutide and semaglutide include their growing role in diabetes and obesity treatment due to ...
While the expanded approval fulfills an unmet meet in postmenopausal women, its benefits are marginal in that population.
Emerging opportunities include advancing semaglutide in type 2 diabetes and obesity treatment, focusing on oral and injectable forms, biosimilar competition, digital adherence solutions, and robust ...
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...
The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...
Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct ...
US FDA approves Roche’s Lunsumio VELO for subcutaneous use in relapsed or refractory follicular lymphoma: Basel Tuesday, December 23, 2025, 13:00 Hrs [IST] Roche announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback